All In Biotech

Free tool

FAERS Monitor: Opill

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017031 or its brand name (Opill, Norgestrel). Reports on generic versions are filed under their own applications.

Reports

1,356

Serious

302

22% of reports

Hospitalization

23

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • heavy menstrual bleeding245
  • pregnancy on oral contraceptive206
  • intermenstrual bleeding182
  • polymenorrhoea155
  • product dose omission issue79
  • nausea77
  • adverse drug reaction68
  • headache66
  • weight increased63
  • acne53
  • dysmenorrhoea52
  • menstruation irregular51
  • product use in unapproved indication47
  • muscle spasms40
  • vaginal haemorrhage40

Reports by year received

View as table
YearReports
20042
20051
20081
20104
20113
20122
20135
20142
20156
20164
20171
20182
20192
20204
20212
20224
20234
2024349
2025937
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,803 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pregnancy on oral contraceptiveSignal2061322.71159.2249,520
polymenorrhoeaSignal155725.7623.4106,493
intermenstrual bleedingSignal182522.1454.991,102
heavy menstrual bleedingSignal245434.2386.9102,625
dysmenorrhoeaSignal5261.146.83,003
menstruation irregularSignal5129.622.61,379
vaginal haemorrhageSignal4014.310.5482
adverse drug reactionSignal6811.89.3660
acneSignal5310.88.3465
weight increasedSignal634.43.4162
product dose omission issueSignal794.23.4190
muscle spasmsSignal403.42.565
product use in unapproved indicationSignal472.92.259
headache661.61.316
nausea771.51.213

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.